HOLLISTON, Mass., Feb. 23, 2017 -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its fourth quarter 2016 after market trading hours on Thursday, March 9, 2017. A conference call to discuss the company's fourth quarter 2016 financial results and its operations is scheduled for that same date at 4:30 PM ET. On that call, management may respond to questions from the audience and provide information on any of a number of topics related to the business, including operations, plans and outlook.
Participating in the call will be Jeffrey A. Duchemin, President and Chief Executive Officer; and Robert Gagnon, Chief Financial Officer of Harvard Bioscience. Investors can access the live conference call by dialing the following phone numbers: toll-free 1-800-708-4539, or international: 1-847-619-6396, and referencing the conference ID# 44422279.
The conference will be simultaneously webcast and can be accessed through the Harvard Bioscience website. To listen to the webcast, log on to the webcast at:
http://investor.harvardbioscience.com/
and click on the Earnings Call icon. Financial information presented on the call, including the earnings release, will also be available on the investor relations section of the website.
If you are unable to listen to the live conference call, the webcast will be available on the Company's website through March 16, 2017.
To add this meeting to your calendar visit: http://investor.harvardbioscience.com/ and click “remind me”.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, GE Healthcare, and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.
CONTACTS: Jeffrey A. Duchemin CEO and President Robert E. Gagnon CFO Corey Manchester Director, Finance and Investor Relations Tel: 508 893 8999


China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards
Nvidia and Groq Strike Strategic AI Inference Licensing Deal
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 



